How to evaluate an AI scribe for community health services: a compliance and procurement checklist

Legal uncertainty is now the single biggest barrier to AI adoption in European health systems, cited by 86% of the 50 countries surveyed in WHO/Europe's 2024–2025 assessment of AI readiness, ahead of even cost (78%). For community health services, nurse-led, dispersed across schools, home visits, and local clinics, and accountable to population-level mandates rather than individual episode metrics, that uncertainty is sharper still.

Most of the published evidence on AI documentation tools comes from hospitals and GP practices, settings with fixed rooms, reliable connectivity, and protected documentation time that community services simply don't have. This guide sets out what public health and community service administrators actually need to assess, in the order to assess it.

First: be precise about what the tool does

An AI documentation assistant listens to a clinical conversation, converts speech to text, and drafts a structured note for the clinician to review. What it does not do is interpret findings, suggest diagnoses, recommend treatment, or flag clinical risk. Those functions are clinical decision support, and they carry different regulatory obligations under both the EU Medical Device Regulation and the EU AI Act.

A practical test: if you removed the tool's output from a consultation and the clinician's clinical judgement was unchanged, it's a documentation assistant. If the output would change what the clinician does next, it's decision support. Getting this distinction wrong at the start creates compliance errors that are expensive to unwind later.

Step 1: MDR classification

The central question is whether the tool has a medical intended purpose: diagnosis, prevention, monitoring, treatment, or alleviation of disease. A tool that only captures and structures conversation generally sits outside MDR scope; one that generates recommendations or risk scores sits inside it.

The European Commission's MDCG 2025-6 guidance confirms that where a tool does qualify as a medical device, MDR and AI Act obligations apply simultaneously, and compliance with one doesn't satisfy the other. Where a tool is a device, it needs CE marking, a completed conformity assessment, and post-market surveillance.

Ask any vendor for a written statement of intended purpose, confirmation of their MDR classification and its basis, CE marking documentation if applicable, and evidence of any Notified Body involvement. Don't assume CE marking is imminent if it hasn't been granted: Osborne Clarke's analysis notes a genuine bottleneck in Notified Bodies able to assess AI-based devices under both frameworks. We've covered the MDR, GDPR, and AI Act interplay in more depth separately.

Step 2: GDPR, data residency, and the DPIA

An AI scribe processes special category health data under GDPR Article 9, triggering the most stringent tier of obligations, with the community service as data controller bearing primary accountability. Before procurement, resolve five things:

• Lawful basis. Community health programmes typically rely on Article 9(2)(h), processing necessary for healthcare provision, alongside Article 6(1)(e) for public task. Confirm with your Data Protection Officer that this is documented.

• Data Processing Agreement. An Article 28-compliant DPA must be signed before any data flows, specifying purpose, duration, data types, and controller/processor obligations.

• Data residency. Require contractual guarantees that patient data is stored and processed within the EU/EEA (or the UK for UK services), and a full list of sub-processors, including cloud providers, with their locations.

• Retention. Confirm what the tool keeps after a consultation, for how long, and under what deletion policy.

• DPIA. A Data Protection Impact Assessment under Article 35 is mandatory here, since AI processing of health data at scale is high-risk by definition. In the UK, the ICO's guidance on AI and data protection sets out what a DPIA for an AI system needs to cover.

The European Health Data Space, in force since 2025, adds a further governance layer for EU services where patient data may cross borders.

Step 3: security

ISO 27001 is the baseline: ask for the current certificate, its scope, and the date of the last surveillance audit. Beyond that, get written answers on who inside the vendor can access patient data and under what audit trail, whether data is encrypted in transit and at rest, whether the service can access processing logs, the vendor's contractual breach-notification commitment (GDPR requires regulatory notification within 72 hours, so the vendor must support that), and how often independent penetration testing happens.

National health-data security frameworks in countries like France, Germany, and the Netherlands may sit on top of ISO 27001, so check whether yours applies.

Step 4: does it actually work in community settings?

This is where hospital evidence stops transferring. Community health encounters happen in patients' homes and school clinics, not fixed acoustic environments, so background noise and variable microphone quality affect transcription accuracy in ways a controlled room doesn't.

Connectivity is often unreliable, so establish whether the tool works offline and syncs later. Consultations are shorter and more conversational. Staff frequently span clinical assessment, social care coordination, and public health monitoring in a single visit, so note templates need to reflect that breadth. Devices may be shared or personal rather than fixed and managed.

Ask vendors directly whether the tool has been deployed in community health, home visiting, or school health contexts, and request performance data from those settings specifically. NHS England's guidance on ambient scribing is a useful UK reference for what a responsible evaluation should include, and Tandem's own AI scribe documentation sets out how it handles integration and data handling for exactly this kind of assessment.

Step 5: language and population diversity

Community services often serve linguistically diverse populations. A tool that performs well in standard Dutch, German, or English may perform materially worse with accented speech, regional dialects, or code-switching.

For a service with a population health mandate, uneven accuracy isn't a technical footnote, it's an equity issue. Ask which language variants the tool has been validated in, what the documented accuracy differential is between standard and non-standard speech, and how it handles interpreter-mediated consultations.

Test with staff and patients who reflect your actual population, not only the majority language group.

Step 6: a structured pilot, with thresholds set in advance

Don't outsource accuracy assessment to the vendor. Define what a satisfactory note looks like for each encounter type in your service, then run a time-limited pilot with real consultations, independent review of AI-generated notes against clinician recall, and structured logging of errors, omissions, and hallucinations (content the AI generates that was never said).

Crucially, set your acceptance threshold before the pilot starts, so poor results can't be rationalised after the fact. Build ongoing sample review into governance from day one. The clinician who conducted the encounter remains fully accountable for the note; the AI output is a draft for review, never a final record, and that needs stating unambiguously in training.

Step 7: governance and procurement sequence

Engage the DPO at the start, not the end. Then the clinical governance lead (to own quality standards and the pilot), IT and security (integration feasibility), legal (contracts, DPA, liability under MDR and the AI Act), procurement (public procurement rules above threshold values), and clinical staff representatives (requirements and pilot design).

WHO/Europe found 81% of EU Member States already involve stakeholders in shaping AI governance; the same principle applies at service level. Your business case should cover quantified documentation burden reduction, retention and burnout as a workforce argument, compliance as a risk obligation rather than an optional extra, and the cost of notacting.

The short checklist

Before go-live, you should be able to answer yes to all of these:

• Written intended-purpose statement and MDR classification received; AI Act classification assessed

• DPIA started and owned by the DPO; Article 28 DPA ready; EU/EEA (or UK) residency and full sub-processor list confirmed in writing

• Current ISO 27001 certificate in scope; access controls, audit logs, breach timelines, and pen-test schedule confirmed

• Evidence of performance in community, home-visit, or school health settings, and offline capability confirmed

• Validated in your population's languages, tested with representative staff and patients

• Pilot designed with acceptance thresholds set in advance, and an ongoing review process in place

• DPO, clinical governance, IT, legal, procurement, and staff representatives all engaged

WHO/Europe's finding that 92% of countries want clearer liability rules says something honest about where the sector is: the regulatory ground is still settling. That's an argument for starting with a clear, sequenced framework rather than a technology-first purchase, not for waiting.

The Lancet Primary Care framework emphasises that AI tools in primary and community care must be assessed against the actual delivery model, not a generalised clinical encounter. Done in this order, the assessment protects the service legally and produces a deployment that's genuinely useful to the nurses and communities it's meant to serve.

Frequently asked questions

▶ Why do municipal community health programmes need a separate evaluation framework for AI documentation tools?

Because most of the evidence comes from hospitals and GP practices, with fixed rooms, dedicated IT, and protected documentation time. Community health is nurse-led, spread across homes and school clinics, and built around brief, informal encounters with intermittent connectivity. A tool validated in a hospital can't be assumed to perform the same way there.

▶ What does an AI documentation assistant actually do in a community health setting?

It listens to the consultation, converts speech to text, and drafts a structured note for the clinician to review. It doesn't interpret findings, suggest diagnoses, or flag risk; those functions are clinical decision support, which carries different regulatory obligations. A useful test: if removing the tool's output wouldn't change the clinician's judgement, it's a documentation assistant.

▶ How does the EU Medical Device Regulation (MDR) apply to AI documentation tools?

It turns on intended purpose. A tool that only captures and structures conversation generally sits outside MDR scope; one that generates recommendations or risk scores sits inside it, and needs CE marking and a conformity assessment. Where a device also qualifies as high-risk under the AI Act, the Commission's MDCG 2025-6 guidance confirms both frameworks apply at once.

▶ What GDPR obligations apply when a municipality uses an AI documentation assistant to process patient data?

Health data is special category data under Article 9, the most stringent tier. The service, as controller, needs a documented lawful basis (typically Article 9(2)(h) with Article 6(1)(e)), an Article 28 Data Processing Agreement signed before any data flows, confirmed EU/EEA (or UK) residency, a full sub-processor list, and a mandatory Article 35 DPIA. The ICO's AI guidance sets out what that DPIA should cover.

▶ What security certifications and controls should administrators require from AI documentation vendors?

ISO 27001 as the baseline, with the current certificate, scope, and last audit date. Beyond that, written confirmation of encryption in transit and at rest, logged and controlled access to patient data, a breach-notification commitment that supports GDPR's 72-hour rule, and regular independent penetration testing. National frameworks in countries like France, Germany, and the Netherlands may add requirements on top.

▶ Why might a hospital-validated AI documentation tool perform differently in community health settings?

Home visits and school clinics mean variable acoustics, unreliable connectivity, shorter and more conversational encounters, and staff covering clinical, social care, and public health work in one visit. Ask vendors for performance data from those settings specifically, not hospital environments.

▶ Who is accountable for the accuracy of AI-generated clinical notes in a nurse-led community health service?

The clinician who conducted the encounter, fully and without exception. The AI output is a draft for review, never a final record, and that needs stating unambiguously in training. Technical training alone isn't enough; staff also need supported experience to spot when a note doesn't reflect what actually happened.

▶ How should administrators evaluate AI documentation tool accuracy before deploying across a community health programme?

Define what a satisfactory note looks like for each encounter type, run a time-limited pilot on real consultations with independent review, log errors, omissions, and hallucinations, and set your acceptance threshold before the pilot starts so results can't be rationalised afterwards. Then build ongoing sample review into governance permanently.

▶ How do we assess whether a tool can serve linguistically diverse community health populations?

Ask which language variants it's validated in, what the accuracy differential is between standard and non-standard speech, and how it handles interpreter-mediated consultations. Then test with staff and patients who reflect your actual population, not only the majority language group. For a service with a population health mandate, uneven accuracy is an equity issue, not a technical footnote.

▶ Which internal stakeholders need to be involved in procurement?

The DPO from the very start (owning the DPIA), a clinical governance lead (quality standards and the pilot), IT and security (integration), legal (contracts and liability under MDR and the AI Act), procurement (public procurement rules), and clinical staff representatives shaping requirements from the beginning. WHO/Europe found 81% of EU Member States already involve stakeholders in AI governance; the same principle applies at service level.